Saußele S, Silver Richard T
III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Pettenkoferstr. 22, 68169, Mannheim, Germany,
Ann Hematol. 2015 Apr;94 Suppl 2:S159-65. doi: 10.1007/s00277-015-2324-0. Epub 2015 Mar 27.
Due to the high efficacy of BCR-ABL tyrosine kinase inhibition (TKI) in chronic phase (CP) chronic myeloid leukemia (CML), the frequency of blast crisis (BC) is greatly reduced compared to the pre-TKI era. However, TKI treatment of BC has only marginally improved the number of favorable responses, including remissions, which for the most part have only been transitory. Occasionally, they provide a therapeutic window to perform an allogeneic stem cell transplantation (allo-SCT). The challenge remains to improve management of BC with the limited options available. We review and summarize articles pertaining to the treatment of BC CML published after 2002. Additionally, we will discuss whether there is a need for a new definition of BC and/or treatment failure.
由于BCR-ABL酪氨酸激酶抑制剂（TKI）在慢性期（CP）慢性髓性白血病（CML）中具有高效性，与TKI治疗前的时代相比，急变期（BC）的发生率大幅降低。然而，TKI治疗BC仅略微改善了包括缓解在内的良好反应数量，而这些缓解大多只是暂时的。偶尔，它们会提供一个进行异基因干细胞移植（allo-SCT）的治疗窗口。利用有限的可用选择改善BC的管理仍然是一项挑战。我们回顾并总结了2002年后发表的有关CML急变期治疗的文章。此外，我们将讨论是否需要对急变期和/或治疗失败进行新的定义。
